Screener
Edgewise Therapeutics, Inc. EWTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
FAQ
- What is Edgewise Therapeutics, Inc.'s EPS (diluted)?
- Edgewise Therapeutics, Inc. (EWTX) reported EPS (diluted) of -$0.46 in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Edgewise Therapeutics, Inc.'s EPS (diluted) decreased by 7.0% year-over-year, from -$0.43 to -$0.46.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s EPS (diluted) has grown at a -24.6% compound annual growth rate (CAGR), from -$5.08 to -$1.64.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Edgewise Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude